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Gene Therapy in Patient-specific Stem Cell Lines
and a Preclinical Model of Retinitis Pigmentosa
With Membrane Frizzled-related Protein Defects
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Defects in Membrane Frizzled-related Protein (MFRP)
cause autosomal recessive retinitis pigmentosa (RP). MFRP
codes for a retinal pigment epithelium (RPE)-
specific
membrane receptor of unknown function. In patientspecific induced pluripotent stem (iPS)-derived RPE cells,
precise levels of MFRP, and its dicistronic partner CTRP5,
are critical to the regulation of actin organization. Overexpression of CTRP5 in naïve human RPE cells phenocopied behavior of MFRP-deficient patient RPE (iPS-RPE)
cells. AAV8 (Y733F) vector expressing human MFRP rescued the actin disorganization phenotype and restored
apical microvilli in patient-specific iPS-RPE cell lines. As a
result, AAV-treated MFRP mutant iPS-RPE recovered pigmentation and transepithelial resistance. The efficacy of
AAV-mediated gene therapy was also evaluated in Mfrprd6/Mfrprd6 mice—an established preclinical model of
RP—and long-term improvement in visual function was
observed in AAV-Mfrp-treated mice. This report is the
first to indicate the successful use of human iPS-RPE cells
as a recipient for gene therapy. The observed favorable
response to gene therapy in both patient-specific cell
lines, and the Mfrprd6/Mfrprd6 preclinical model suggests
that this form of degeneration caused by MFRP mutations is a potential target for interventional trials.
Received 1 September 2013; accepted 23 May 2014; advance online
publication 8 July 2014. doi:10.1038/mt.2014.100

INTRODUCTION
Induced pluripotent stem (iPS) cells reprogrammed from somatic
cells have allowed for the generation of patient-specific disease
cells in vitro. Interest in generating human-induced pluripotent
stem (hiPS) cells for stem cell modeling of diseases has overtaken
that of patient-specific human embryonic stem cells due to the
ethical, technical, and political concerns associated with the latter.

As a platform to study patient-specific targeted disease cells, hiPS
cells have exciting potential in regenerative medicine and human
disease modeling. The in vitro phenotype of disease-specific iPSderived cells can be used to bridge the knowledge gap between the
clinical phenotype and molecular or cellular mechanisms, along
with further applications, such as creating new strategies for drug
screening or developing novel therapeutic agents.1 By using hiPS
cells, we can prove that a disease is caused by a gene mutation and
hypothesize potential treatment options before using more expensive animal studies.2 The hiPS cell-based disease models may also
assist in the development of novel treatments for clinical trials.3–5
Retinitis pigmentosa (RP), which affects approximately 1.5
million people worldwide, can have autosomal dominant, autosomal recessive, or X-linked inheritance patterns. To date, over 60
genes have been linked to the autosomal and X-linked forms of RP,
of which over half (35) are associated with the recessive pattern
of inheritance. One such discovered gene is Mfrp (MIM 606227),
which encodes a retinal pigment epithelium (RPE)-specific membrane receptor of unknown function.6,7 The MFRP gene encodes a
type II transmembrane protein similar to WNT-binding frizzled
proteins. This protein is encoded in a dicistronic transcript, which
also contains the complete open reading frame (ORF) of the complement C1q tumor necrosis factor-related p
 rotein-5 (C1QTNF5/
CTRP5) (MIM 608752) in the 3’-untranslated region.8,9 MFRP
and CTRP5 colocalize on within the RPE and ciliary bodies
and interact directly with each other.7,9–11 MFRP and CTRP5 are
thought to exist in an antagonistic relationship,7,9,10,12 but there is
no direct proof published at this time.
Mfrprd6/Mfrprd6 mice have a 4-base pair (bp) deletion in the splice
donor sequence on intron 4. The subsequent absence of exon 4 causes
a deletion of 58 amino acids in the MFRP protein.9 These mice have
autosomal recessive, progressive retinal degeneration, which is evident from white spotting visualized during fundus examination. As a
result, these mice lose photoreceptors with age. Histological analysis
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shows that the 12–14 cell layers found at birth decline to 4–5 layers
by 4.5 months, 2–4 layers by 7 months, and 1 layer by 24 months.
Beginning at 1 month, rod and cone photoreceptor function is progressively lost, and function is completely absent by 70 weeks.9 As a
preclinical model of RP, Mfrprd6/Mfrprd6 mice are ideal recipients to
test in vivo treatment for RP caused by MFRP deficiency.
For human genetic diseases, uncovering the relationship
between functionally related proteins is a step toward further
understanding the mechanisms of disease and potential t reatment.
The goal of this study is to use hiPS cell technology to elucidate
the role of a novel mutation in the MFRP gene and its putative
association with RP. Modeling pathogenesis and treatment in vitro
using patient-specific iPS cells will help to decrease patient risk,
clarify disease mechanisms, bypass problems related to differences
among species that arise when using animal models, and reduce
the cost of clinical trials. In this study, we generated iPS cells from
two RP patients with MFRP mutations, treated their iPS-RPE cells
with AAV vector therapy, and used their iPS-RPE cells to identify
MFRP downstream targets.

c

RP in a 19-year-old man (Patient 1, P1) and a 50-year-old woman
(Patient 2, P2) was diagnosed by the coauthors (SHT, IHM,
QVH, and LAY). P1 showed a relative preservation of his retina
compared to other forms of RP (Figure 1a). He did not exhibit
significant loss of the photoreceptor nuclear layer but had cystic
degeneration of the macula seen on optical coherence tomograms
(OCT) (Figure 1e). Full-field electroretinogram (ERG) analysis
of P1 showed extinguished scotopic rod-specific amplitudes but
relative sparing of cone responses (Figure 1f). P2 showed macular
atrophy and extensive subretinal salt-and-pepper RPE mottling
(Figure 1b). DNA sequencing of MFRP revealed that P1 carried
a novel homozygous IVS10 +5G>A mutation in the MFRP gene
(Figure 1c). We confirmed this mutation by DNA sequencing of
the MFRP gene on parents of P1, and both of the parents were
heterozygous IVS10 +5G/A (Supplementary Figure S1). P2 carried a homozygous, 1-bp del (492C mutation) in the MFRP gene
(Figure 1d).
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Figure 1 Fundus examination of two MFRP-mutant patients. (a) Color fundus photographs from Patient 1, P1. OD (right eye) (left picture) and
OS (left eye) (right picture) show relative preservation of the retina compared to other forms of RP. (b) Fundi from Patient 2, P2, OD (left picture) and
OS (right picture) show typical para-arterial intraretinal migration, macular atrophy, and extensive subretinal salt-and-pepper RPE mottling. (c) Partial
electropherogram of IVS10 of the MFRP gene with the normal sequence (left) and a G-A +5 mutation (pointed by red arrow) in P1 (right). (d) Partial
electropherogram of exon 5 in the MFRP gene with the normal sequence (left) and a homozygous 1-bp del (492C) (pointed by red arrow) in P2 (right).
(e) Optical coherence tomography (OCT) of the macula in P1 shows cystic degeneration and thickening of the foveal region. (f) Full-field electroretinogram (ERG) analysis of P1 shows extinguished scotopic rod-specific amplitudes but relative sparing of cone responses.
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Patient-specific cell lines
Fibroblast cells from skin samples of P1 and P2 were transduced
with lentiviruses carrying the reprogramming genes OCT4, SOX2,
c-MYC, and KLF4 to establish patient-specific iPS cell lines; fibroblasts from a healthy donor’s biopsy sample (female, 56-year-old)
were also cultured and reprogrammed in the same way to generate a
wild-type control iPS line. Immunocytochemistry analysis, followed
by confocal microscopy, demonstrated that all undifferentiated iPS
lines expressed the pluripotent markers Oct-4, Sox-2, SSEA4, TRA1-60, and NANOG (Figure 2a). Teratoma assays confirmed the pluripotency of each iPS line (Supplementary Figure S2).
Following differentiation, pigment clusters derived from iPS
cells appeared after 6–8 weeks. Under light microscope, the wildtype control iPS-RPE showed native RPE morphological characteristics, including perinuclear localization of melanin granules. In
contrast, iPS-RPE cells from both P1 and P2 had abnormal morphology with less pigment, mislocalized pigment distribution, and
loss of clear cellular boundaries and cell-to-cell contact (Figure 2b).
Immunoblot analyses for the native, mature RPE-specific markers RPE65, BESTROPHIN-1, MITF, and VINCULIN confirmed
the RPE fate of iPS-RPE cells from wild-type control, P1 and P2
(Figure 2c, quantification shown in Supplementary Figure S3).

40 (SV40) site, and a polyA tail flanked by inverted terminal
repeats (ITRs) (Figure 3). In this report, the AAV2/8(Y733F).
CMV.huMFRP.SV40 vector will be referred to as AAV-MFRP, the
AAV2/8(Y733F).CMV.huCTRP5.SV40 vector will be referred to
as AAV-CTRP5, and the AAV2/8(Y733F).CMV.mMfrp.SV40 vector will be referred to as AAV-Mfrp.

Label-free mass spectrometric proteome profiling
Label-free shotgun proteomic profiling provided data to identify
key proteins from thousands of proteins and discern differences
in protein expression phenotypes across cell lines with various
genotypes.16 β-actin emerged as the most significant differentially-expressed protein in iPS-RPE lines derived from our two
MFRP-mutant patients; its level was two-fold higher compared to
wild-type control iPS-RPE. No other protein in the dataset had
this striking pattern of expression β-actin as a candidate in MFRP
signaling pathway. Immunoblot analyses confirmed the results
from the proteomic profiling: similar patterns were observed in
β-actin expression (Figure 4a), with increased level in iPS-RPE
derived from our two MFRP-mutant patients compared to wildtype control iPS-RPE.
MFRP level is inversely proportional to CTRP5
expression in RPE cells
To explore the relationship between MFRP and CTRP5 in RPE
cells, antibodies to MFRP and CTRP5 were used to probe extracts
from iPS-RPE, human autopsy RPE, and AAV-MFRP-transduced

AAV2/8(Y733F) gene therapy vectors
The AAV2/8(Y733F)-CMV gene transfer vector13–15 was based
on pZac2.1. MFRP, CTRP5, or Mfrp cDNA was cloned into this
expression cassette along with the CMV promoter, a Simian virus
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Figure 2 Establish patient-specific cell lines. (a) Representative immunofluorescence image of pluripotency markers in established patient-specific
iPS cell line. Scale bar: 100 μm. (b) Light microscopy images of cultured human iPS-RPE cells from a wild-type control donor (left), P1 (middle), and
P2 (right). For upper panel, scale bar: 50 μm; lower panel, scale bar: 100 μm. (c) Immunoblot analysis of mature RPE specific marker RPE65 (65 kDa),
BESTROPHIN-1 (68 kDa), MITF (59kDa), and VINCULIN (124 kDa) in iPS-RPE cells from wild-type control donor (WT), P1, and P2. GAPDH serves as
the loading control.
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Figure 3 Schematic representation of the AAV2/8(Y733F)-CMV-vector. A pZac2.1 vector plasmid displaying the complementary DNA (cDNA)
of human MFRP. (a), human CTRP5 (b), and mouse Mfrp (c) fragments driven by the CMV promoter. The Simian virus 40 (SV40) polyadenylation
signal is located at the 3′ end of the cDNA. Arrows indicate the direction of transcription, and the 5′- and 3′-inverted terminal repeat (ITRs) of AAV
are shown.

HEK293 cells. Immunoblotting results presented that MFRP and
its dicistronic gene CTRP5 existed in an antagonistic relationship to regulate actin organization. Lack of MFRP expression
with corresponding increases in CTRP5 and β-actin levels were
observed in iPS-RPE cells derived from both P1 and P2 compared
to wild-type control iPS-RPE. When naive human RPE cells, isolated from an autopsied eye, were transduced with AAV-CTRP5,
a decrease in the MFRP and increase in CTRP5 and β-actin levels
was observed compared to nontransduced controls. Strong MFRP
expression and null CTRP5 expression was observed in HEK293
cells transduced with AAV-MFRP, which served as a positive
control for AAV-mediated transgene expression, despite loading
at 20% concentration compared to the RPE experiments. In all
lanes, CTRP5 expression opposed MFRP expression. Mature RPE
fates were further confirmed by the expression of RPE-specific
protein, CRALBP, in all iPS-RPE cells and autopsied RPE, yet not
in HEK293 cells. The RPE from an autopsied eye with nontreated
and wild-type control iPS-RPE cells served as the positive control
(Figure 4a, quantification shown in Supplementary Figures S3
and S4).

Overexpression of CTRP5 phenocopies the MFRP
deficiency
In immunoblots, overexpression of CTRP5 led to down-regulation of MFRP in AAV-CTRP5 transduced human autopsy RPE
cells. To confirm the relationship between MFRP and CTRP5,
immunofluorescence for rhodamine-phalloidin was performed
on the wild-type control iPS-RPE, MFRP-deficient iPS-RPE (P1),
and human autopsy RPE before and after AAV-CTRP5 treatment.
Under fluorescence microscopy, the wild-type control iPS-RPE
and nontreated human autopsy RPE showed similar morphology:
organized actin filaments arranged in dense bands around the cell
periphery and actin stress fibers extending throughout the cytoplasm. Both iPS-RPE cells from P1 and AAV-CTRP5 transduced
human autopsy RPE showed disorganized and elongated crisscrossing actin stress fibers, increased numbers of focal adhesions,
and loss of cell-to-cell contact (Figure 4b).
AAV-MFRP gene therapy rescues dysmorphic MFRPdeficient iPS-RPE cells
iPS-RPE cells from the two MFRP mutant patients and the
Mfrprd6/Mfrprd6 mouse were found to be pleiotropic compared to
Molecular Therapy vol. 22 no. 9 sep. 2014

the hexagonal RPE cells derived from wild-type control iPS-RPE
and C57BL/6(B6) mice controls. Flat mount of RPE immunolabeled for tight-junction zonula occludens (ZO-1) protein from a
Mfrprd6/Mfrprd6 mouse shows marked variation in cell size compared to the RPE from adult B6 mice, which served as controls
(Figure 5a). In iPS-RPE, the hexagonal red structure indicates
the presence of ZO-1 on wild-type control iPS-RPE cells. Cellular
morphology is lost in iPS-RPE cells from P1 and P2, but the regular hexagonal pattern of ZO-1 expression was restored in dysmorphic iPS-RPE cells from P1 and P2 following AAV-MFRP vector
treatment (Figure 5b). Microfilament organization of RPE cells
was assessed by immunofluorescence analysis with rhodaminephalloidin staining. Wild-type iPS-RPE shows precisely organized
β-actin filaments arranged in dense bands around the cell periphery with short actin stress fibers extending throughout the cytoplasm. MFRP-deficient iPS-RPE from P1 and P2 exhibit elongated
crisscrossing actin stress fibers, increased numbers of focal adhesions, and loss of cell-cell contact. AAV-MFRP treatment restored
actin filament bundle organization to the iPS-RPE from P1 and
P2. After AAV-MFRP treatment, iPS-RPE cells from P1 and P2
exhibited hexagonal, organized actin filaments around the cell
periphery (Figure 5c).
Supernumerary microvilli were observed in Mfrprd6/Mfrprd6
mice.17 However, human iPS-RPE cells from P1 and P2 showed
a loss of apical microvilli, which was restored after AAV-MFRP
treatment (Figure 6). Wild-type iPS-RPE cells were used as a
control.
In trans-well culture system, wild-type control iPS-RPE cells
exhibit strong pigmentation whereas the iPS-RPE from P1 and P2
showed significant loss of pigment. Strikingly, after AAV-MFRP
transduction, MFRP-mutant iPS-RPE cells regained pigmentation
(Figure 7a).
Patients with MFRP deficiency lost the RPE barrier function
and developed cystic degeneration in their maculae (Figure 1e).
Transepithelial resistance (TER) reveals the status of RPE tight
junctions. In order to quantify the functional impact of AAVMFRP rescue, we used TER to reveal the status of tight junctions
between iPS-RPE cells treated with and without AAV-MFRP.
TER in the wild-type control iPS-RPE increased to 320Ω cm−2
over 5 weeks. The iPS-RPE from both P1 and P2 showed a significant improvement (P value = 0.0001183 for P1, and P value
= 0.000341 for P2) at all weeks tested for cells transduced with
1691
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Figure 4 Immunoblots and immunofluorescence on MFRP-deficient
and CTRP5-overexpressed RPE cells. (a) Antibodies to MFRP, CTRP5,
β-actin, CRALBP (RPE-specific marker), and GAPDH were used to
probe extracts from iPS-RPE from P1, P2 and the wild-type control
donor (lanes 1-3), autopsy RPE without and with AAV-CTRP5-treated
(lanes 4-5), and HEK293 cells transduced with AAV-MFRP (lane 6). (b)
Immunofluorescence for rhodamine-phalloidin on wild-type iPS-RPE
cells (upper left), MFRP-deficient iPS-RPE cells from P1 (upper right),
human autopsy RPE (bottom left) and human autopsy RPE treated with
AAV-CTRP5 vector (bottom right). Scale bar = 10 μm.

the AAV-MFRP vector compared to untreated cells. The TER at
5 weeks for the AAV-transduced group reached 64 Ω cm−2 for P1
and 70 Ω cm−2 for P2 (Figure 7b).

AAV-Mfrp provides long-term vision rescue in a
preclinical model of RP
Quantitative autofluorescence (AF) images in Mfrprd6/Mfrprd6 mice
showed an increase in punctate and general lipofuscin accumulation
at 30, 60, and 90 days of age (Figure 8a). To prevent photoreceptor
cell death in Mfrprd6/Mfrprd6 mice, the right eyes were transduced
by subretinal injection of the AAV-Mfrp vector on postnatal day 5.
1692

Patient 2

CTRP5-overexpressed

Autopsy RPE

Wild-type

Figure 5 Immunofluorescence on RPE without and with AAV-MFRP
treated. (a) A flat mount of a RPE sheet immunolabeled for tight-junction protein ZO-1 from C57BL/6 (B6) mice (left), serve as control and an
Mfrprd6/Mfrprd6 mouse (right). Scale bar: 100 μm. (b) Immunofluorescence
staining for ZO-1 (red) and nuclear DAPI staining (blue) on iPS-RPE monolayer from wild-type control donor, P1, P2, and iPS-RPE from P1 and P2
after AAV-MFRP treatment. Scale bar: 50 μm. (c) Rhodamine-phalloidin
immunofluorescence to assess microfilament organization on iPS-RPE
cells from control donor, P1, P2, and iPS-RPE from P1 and P2 after AAVMFRP treatment. Scale bar: 10 μm.

Compared to the control left eyes of the Mfrprd6/Mfrprd6 mice, AAVMfrp transduction decreased background AF and resulted in fewer
punctate signals in the treated eye (Figure 8b). Quantification of
AF showed a significantly decreased AF from a density–volume
of 137.01 to 43.59 (P value = 0.02) (Figure 8c). Composite darkadapted electroretinograms (ERGs), which served as a direct
proof of retina function, were performed two months after unilateral subretinal injection of wild-type Mfrp via the AAV-Mfrp
vector. The other eye served as the untreated control. Rod-specific
response and maximum response ERGs were recorded for 11 mice.
The function of both rod and cone photoreceptors increased significantly, as evidenced by an increased amplitude of the a-wave
www.moleculartherapy.org vol. 22 no. 9 sep. 2014
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and testing of gene therapy vectors. In this study, we described a
human iPS cell model of MFRP-deficient RP that possessed functional deficiencies consistent with the clinicopathological features
of the disease.10,11,15 Focusing on an RPE-based disease model
presents several advantages. iPS-RPE can be reproducibly isolated and closely monitored both morphologically and functionally before experiments, effectively minimizing variability in the
timing of differentiation. In addition, the RPE, unlike many other
human cell types, has a well-described culture standard, ensuring
proper controls.18,19
Our study accomplished four objectives. First, it described
the successful characterization of human-derived iPS cells from
two RP patients, one of them with a novel mutation in the MFRP
gene, homozygous IVS10 +5G>A, which had never been reported
before. Second, it demonstrated that iPS-derived cells could be
used as surrogate endpoints for FDA trials and a platform for
in vitro testing of AAV vectors. Third, this study identified actin
organization as a downstream target of MFRP and demonstrated
a new putative function of this novel gene related to cytoskeleton
organization. Fourth, this study expounded upon the inverse relationship between MFRP and CTRP5 in human RPE cells.
Traditionally, human genetic diseases were modeled in mice,
but here, we showed that patient-specific cells and a mouse model
did not have the same phenotype. Compared to RPE derived from
wild-type control iPS cells, iPS-RPE from our MFRP patients
exhibited the loss of apical microvilli as observed by electron
microscopy (Figure 6). This result was in stark contrast to the phenotype of the RPE in Mfrprd6/Mfrprd6 mice, which showed higher
densities of apical microvilli.17 Because differences in phenotypic
expression can be observed among species with the same genetic

(from −42.23 to −143 μv) and b-wave (from 182.7 to 343.8 μv)
(Figure 8d). Retinal histology of Mfrprd6/Mfrprd6 mutant retina
and AAV-MFRP-transduced retina presented an increased outer
nuclear layer (ONL) from a thickness of 4-5 nuclei to a thickness of
7–8 nuclei (P = 0.0035) (Figure 8e,f). The rescued photoreceptors
showed improved function and survival for at least 6 months. The
retina sections of AAV2/8(Y733F)-mMfrp-treated Mfrprd6/Mfrprd6
mice showed a clear layer of RPE-specific expression, whereas nontreated Mfrprd6/Mfrprd6 mice did not (Figure 8g). Together, these
data indicate favorable response to gene therapy in both Mfrprd6/
Mfrprd6 preclinical model and patient-specific cells.

DISCUSSION
Human iPS cell technology provides a platform for investigating the pathophysiological mechanisms of genetic mutations
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Figure 6 Transmission electron microscopy of microvilli in patientspecific iPS-RPE without and with AAV-MFRP treatment. AAV-MFRP
treated RPE regain lost microvilli. Scale bar: 1 μm.
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= 0.000341).
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bright strip at the top of each image, enabled intensity comparison. (c) Graphical quantification of AF level in treated and nontreated eyes (P = 0.02).
(d) Rod-specific response and maximum response electroretinograms (ERGs) recordings from 11 Mfrprd6/Mfrprd6 mice that received AAV-Mfrp subretinal injection in right eye at 60 days after the transplantation surgery. Amplitudes of a-wave (**) indicated by letter “a” and b-wave (*) indicated by
letter “b”. (e) Retinal histology (Hematoxylin and eosin staining) of a representative Mfrprd6/Mfrprd6 mutant retina (right panel) and AAV-MFRP transduced retina (left panel). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. (f) Quantification of ONL of AAV-GFP treated,
AAV-Mfrp treated and nontreat eyes in Mfrprd6/Mfrprd6 mice. (g) Representative immunofluorescence pictures of retina histology sections stained by
anti-mouse MFRP from AAV-Mfrp-treated eye (top) and non-treated eye (bottom) of Mfrprd6/Mfrprd6 mice.

mutation, a study of patient-specific cell lines can be complementary to mouse models.
The RPE dysmorphology suggested that patient specific RPE
cells may be more developmentally delayed. Defective MFRP in
both patients and Mfrprd6/Mfrprd6mice affects proper axial length
development. To define the biochemical basis of dysmorphic
RPE, we applied an unbiased proteome screen and identified
actin via mass spectrometry as a potential protein involved in
the MFRP pathophysiological pathway (all Excel data provided
in Supplementary Table S1). To validate the mass spectrometry
results, we used immunoblots to test the protein with significant
up or downregulated status. In all MFRP-deficient and CTRP5overexpressed RPE lines, β-actin was twofold higher than those
wild-type controls. To further confirm the immunoblotting
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results, we performed rhodamine-phalloidin and found that
MFRP-deficient iPS-RPE exhibited increased β-actin expression
and altered actin polymerization in cellular level compared to
wild-type control iPS-RPE (Figure 5). These results reinforce our
novel hypothesis that actin polymerization is a downstream effect
in the MFRP signaling.
The CTRP5 gene is a dicistronic partner of MFRP, and its
secreted protein, CTRP5, has been shown to bind to MFRP.20,21
MFRP and CTRP5 proteins share the functionally related CUB
and C1q domains. In prokaryotes, polycistronic transcripts commonly encode proteins in the same functional pathway, thus constituting an operon. Studies have shown that several dicistronic
transcripts exist in mammals, and most of these genes encode
functionally related proteins. As we mentioned, defects in MFRP
www.moleculartherapy.org vol. 22 no. 9 sep. 2014
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cause autosomal recessive RP. Likewise, the S163R mutation in the
CTRP5 causes late-onset retinal macular degeneration (LORD),
an autosomal dominant condition in humans that closely resembles age-related macular degeneration (AMD).22,23 Secretion of
CTRP5 into the extracellular matrix is impaired by the S163R
mutation, causing an unfolded protein response within the endoplasmic reticulum (ER).20 The heterozygous CTRP5 knock-in
mouse model (Ctrp5+/S163R), similarly as Mfrprd6/Mfrprd6 mice, also
develop RPE abnormalities, early dark adaptation abnormalities, accumulation of hyperautofluorescence spots, drusen, Bruch
membrane abnormalities, and loss of photoreceptors.8,23,24
Like other dicistronic genes, MFRP and CTRP5 may participate in a common biological pathway in RPE, but no functional
relationship between MFRP and CTRP5 has been proposed.
Several studies have confirmed that CTRP5 is a binding partner
of MFRP,7,9,10,12 but here, we provided evidence for an inverse relationship between these two binding partners. Expression of MFRP
in iPS-RPE derived from our two MFRP-mutant patients is lower
compared to wild-type controls. Additionally, CTRP5 levels are
higher in MFRP-deficient iPS-RPE cells compared to wild-type
controls. To validate this finding, we transduced AAV-CTRP5 into
native RPE cells from an autopsy human eye. After two weeks,
we measured the expression level of MFRP and CTRP5 in treated
and nontreated RPE cells. In AAV-CTRP5-transduced RPE cells,
increased CTRP5 expression led to low MFRP levels. In different
independent RPE lines, CTRP5 levels are inversely proportional
MFRP levels.
Besides the expression level, we tested the hypothesis that
MFRP and CTRP5 play the same functional role in RPE cells. From
the result of immunoblots, increased β-actin levels were observed
in both MFRP-deficient RPE cells and CTRP5-overexpressed RPE
cells. We used rhodamine-phalloidin staining to monitor β-actin
level in these RPE cell lines and found that overexpression of
CTRP5 presented similar cellular phenotype as the MFRP deficiency (Figure 4b). We also transduced AAV-CTRP5 into wildtype control iPS-RPE, and also obtained a similar result (images
of autopsy RPE and wild-type iPS-RPE transduced by AAV-GFP
alone as negative control were also included in Supplementary
Figure S5).
In this report, we presented an expeditious system for the
study of a new disease allele using iPS cell technology. By creating a patient-specific model of the disease via iPS, we could study
the phenotypic properties of the disease and its potential treatments on a virtually unlimited sample of cells. Following our
in vitro studies, we used a diseased preclinical model to monitor
physiological responses to the same AAV treatment in vivo. This
approach using human iPS cells to study genetic diseases allowed
for the efficient testing of gene therapy in vitro before studying
live models. In this study, we used patient-specific stem cell lines
to identify two distinct and novel findings concerning MFRP disease: (i) MFRP affects downstream actin polymerization, and (ii)
MFRP coexisted with CTRP5 in an antagonistic, dose-dependent
relationship. While this approach can be used across specialties,
it would be particularly important for inherited retinal degenerative diseases, which are often caused by multiple defects and have
unclear or unknown disease mechanisms. Patient-specific stem
cells represent an incredible resource for gene therapy studies, not
Molecular Therapy vol. 22 no. 9 sep. 2014

Gene Therapy in Patient-specific Stem Cell Lines

only in degenerative disorders of the retina, but also in genetic
disorders of other organ systems.

MATERIALS AND METHODS
Research subjects. Color fundus pictures, optical coherence tomography (OCT), and electroretinogram (ERG) analysis were performed on
two MFRP-related RP patients in the Department of Ophthalmology,
Columbia University Medical Center/New York Presbyterian Hospital.
Skin biopsy samples were obtained (IRB Protocol AAAF1849) from the
two patients and a healthy subject using local anesthesia (lidocaine) and a
biopsy-punch (McKesson, VA). The samples were processed and cultured
as previously described.18,25
The mouse procedures were approved by the Institutional Animal
Care and Use Committee of Columbia University. Mfrprd6/Mfrprd6 mice
were used in accordance with the Statement for the Use of Animals in
Ophthalmic and Vision Research of the Association for Research in
Vision and Ophthalmology.
MFRP sequencing. Genomic DNA from both patients was isolated from

peripheral blood lymphocytes according to standard methods. The entire
coding sequence and exon-intron boundaries of MFRP (13 exons) were
amplified by PCR using pairs of primers that were designed based on the
published consensus sequences.12 Direct sequencing of the PCR-amplified
products was analyzed by the Genwize Company (NJ). All MFRP exon
data are available at Gene Expression Omnibus (MIM 606227).

Generation and maintenance of hiPS cell lines. Primary fibroblasts from
two RP patients and one healthy donor were converted into pluripotent
stem cells using lentiviruses carrying the reprogramming genes OCT4,
SOX2, c-MYC, and KLF4, following the previously established protocol. All
hiPS lines were maintained in hiPSC medium as previously described.18,26
All iPS cells were passaged every 3–4 days.
Differentiation of hiPSC lines. iPS differentiation started at passage 9 for
all iPS lines in this study. For differentiation, hiPS colonies were cultured
as floating clusters in 6-well culture dishes (Costar, Corning, Corning,
NY) pretreated with MEFs in knockout medium (KOM) consisting of
KO-DMEM, 15% KO serum replacement, 1% nonessential amino acids,
2 mmol/l glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin (all from
GIBCO-BRL), and 10 mmol/l nicotinamide (NIC) (Sigma-Aldrich, St
Louis, MO).27 After 6–10 weeks, pigmented clusters were formatted and
plated on 1% matrigel-coated dishes in RPE culture medium according to a
previous protocol28 for a characterization assay. To obtain a monolayer for
the function assay, after 8 weeks of differentiation, the pigmented areas were
isolated manually and plated in 12-well transwell plates (Costar, Corning).
RPE cells derived from iPS cells (iPS-RPE) were maintained in MEM (α
modification, Sigma-Aldrich, M-4526) -based RPE medium, which contains N1 supplement (5 ml per 500 ml medium), Taurine (125 mg per 500 ml
medium), Hydrocortisone (10 μg per 500 ml medium), Triiodo-thyronin
(0.0065 μg per 500 ml medium) (all from Sigma-Aldrich), 2 mmol/l glutamine, 50 U/ml penicillin-streptomycin, 1% nonessential amino acids and
10% fetal bovine serum (all from GIBCO-BRL), for 6–8 weeks to allow
them to form a functional monolayer and to reproduce pigment.
Human autopsy RPE isolation. Human autopsy RPE cells were isolated
and cultured from human eye samples obtained from New York Eye
Bank as described previously.2 In brief, the eyecup, with anterior portions
removed, was incubated at 37 °C for 60 minutes. The retina was then separated from the optic nerve. Next, RPE-Bruch’s membrane and the combined tissues were separated from the choroid layer and transferred to a
15 ml conical tube containing 0.05% trypsin-EDTA. The conical tube was
then incubated in a 37 °C water bath for 10–15 minutes. After centrifugation at 1.4 rpm for 4 minutes, the pellet was then resuspended in RPE
medium and plated on a petri dish.
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Construction of AAV vectors. AAV serotype 2/8 capsids, which contain a

point mutation in the surface-exposed tyrosine residue AAV2/8(Y733F),
were used for packaging the human MFRP, human CTRP5, and mouse
Mfrp constructs. Vector plasmids were constructed by inserting the CMV
promoter region and the full-length MFRP, CTRP5, and Mfrp cDNA
fragments into the pZac2.1 plasmid to generate pZac2.1.CMV.huMFRP.
SV40, pZac2.1.CMV.huCTRP5.SV40, and pZac2.1.CMV.mMfrp.SV40
plasmids.14 The AAV vectors were created, packaged, and purified at the
Penn Vector Corporation (University of Pennsylvania, PA). AAV-GFP vector were obtained from UNC Vector Core Services (University of North
Carolina at Chapel Hill, NC).
Transduction of AAV vectors in vitro. At passage 2, iPS-RPE cells from

P1, P2 and wild-type control had been moved in trans-well culture system
(Costar, 3460). Wild-type control iPS-RPE cells were divided into 4 wells.
iPS-RPE cells from either P1 or P2 were divided into 8 wells, 4 of which
received AAV-MFRP treatment and 4 served as untreated controls. Two
lines of patient-specific iPS-RPE and HEK293 cells also had been grown in
24-well flat dish for AAV-MFRP infection.
All cells mentioned above were infected with the AAV-MFRP vector
at a multiplicity of infection (MOI) of 1 × 104 in serum-free RPE medium.29
After 24 hours, the virus-containing medium was replaced with fresh RPE
medium with 5% serum to continue normal RPE culture. One week later,
the steps mentioned above were repeated. Human RPE cells, isolated from
an autopsied eye shell, were cultured in 6-well plates and infected with
the AAV-CTRP5 vector at an MOI of 1 × 104 as described above. Wildtype control iPS-RPE cells and human autopsy RPE cells were cultured on
cover slip and transduced with the AAV-GFP vector at an MOI of 1 × 104 as
described above.
Transduction of AAV vectors in vivo. To test whether AAV2/8(Y733F)-

mMfrp can restore vision in Mfrprd6/Mfrprd6 mice, we injected
AAV2/8(Y733F)-mMfrp (1.23e12 genome copy/ml) into the subretinal
space of the right eye of Mfrprd6/Mfrprd6 mice at postnatal day 5. Injection
of 1 μl of virus particle suspension into the sclera limbus caused an ideal
bleb detachment at the retinal site of the injection, as evaluated by postsurgical fundus examination. The left eyes of all mice were left untouched and
maintained as a control for experimental analyses. Anesthesia and surgery
were performed as previously described.30
Proteomic analysis. Shotgun proteomic mass spectrometry-based measurements were performed in triplicate on patient specific iPS-RPE and
wild-type control iPS-RPE from P1 and P2. A liquid chromatography-mass
spectrometry (LC-MS) approach was used for the relative quantitation and
simultaneous identification of proteins from all three samples, including
triplicate LC/MS/MS chromatograms (technical replicates) collected for
each of the three biological replicates. We used Synapt G2 quadrupole-timeof-flight mass spectrometry (Waters Corporation, Milford, MA) to compare
proteome subtraction of iPS-derived RPE cell lines from two MFRP mutant
patients and one healthy donor. The data were analyzed with a ProteinLynx
Global Server and TransOmics software (Waters Corporation).
Cells were lysed in M-PER mammalian protein extraction reagent
buffer (cat# 78501; Pierce) with proteinase inhibitor (Roche Diagnostics,
IN). Total protein was quantified using a Bio-Rad protein reader. Protein
samples (20 μg) were then separated on a 10% Tris–Cl gradient gel and
electroblotted onto a nitrocellulose membrane. The membranes were
incubated in blocking buffer for 1 hour at room temperature, washed
three times in PBS + 0.1% Tween for 5 minutes each, and incubated with
primary antibody in blocking buffer overnight at 4 °C. Primary antibodies
against the following proteins were used for western blots: RPE65 (mouse
monoclonal, 1:2,000, Novus Biologicals, Littleton, CO), BESTROPHIN-1
(rabbit monoclonal, 1:500, Abcam, Cambridge, MA), MITF (mouse
monoclonal, 1:500, Abcam), VINCULIN (Rabbit monoclonal, 1:1,000,
Abcam), MFRP (goat polyclonal, 1:1,000, R&D, Minneapolis, MN), CTRP5
(goat polyclonal, 1:1,000, R&D), β-actin (mouse monoclonal, 1:2000,
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Abcam), CRALBP (rabbit polyclonal, 1:400, Santa Cruz, Dallas, TX),
and GAPDH (mouse monoclonal, 1:5,000, Abcam). Mouse, rabbit, and
goat secondary antibodies were obtained from Santa Cruz and used at a
concentration of 1:5,000.
Immunofluorescence. Five antibodies against the pluripotency markers
Oct-4, Sox-2, TRA-1-60, SSEA4, and NANOG (all 1:500, ASK-306, Applied
StemCell, Menlo Park, CA) were used to characterize the iPS cells reprogrammed from the fibroblasts obtained from two MFRP-mutant patients
and the healthy donor as described previously.18 DAPI was used to stain the
cell nuclei. To study the change in cell shape between normal and MFRP
mutant iPS-RPE cells, zonula occludens (ZO)-1 (1:500, 40-2200, Invitrogen
Life Technologies, Grand Island, NY) staining was performed on RPE
isolated from B6 and Mfrprd6/Mfrprd6 mice and iPS-RPE derived from two
MFRP mutant patients before and after AAV2/8-huMFRP treatment. Alexa
Fluor 488-conjugated goat antirabbit or Alexa Fluor 555-conjugated goat
antimouse IgG (1:1,000, Invitrogen, Life Technologies) antibodies were
used as secondary antibodies. Images for staining with all antibodies were
obtained using the same settings with a fluorescence microscope (Leica DM
5000 B, Leica Microsystems, Germany).
Phalloidin staining was performed to distinguish the fibers of RPE cells
in all iPS-RPE lines. The cells were washed two times with PBS and fixed in
4% paraformaldehyde for 10 minutes at room temperature. After washing
with PBS two times, the cells were incubated in 0.1% Triton X-100 and PBS
for 5 minutes. After two subsequent washes with PBS, phalloidin staining
was performed for 30 minutes at room temperature. The phalloidin staining
solution was freshly prepared before use according to the manufacturer’s
instructions (R415, Invitrogen). The stained cells were observed by confocal
microscopy (Zeiss LSM5 Confocal Microscopy, Germany).
Transmission electron microscopy. To monitor apical microvilli of RPE
cells, transmission electron microscopy (TEM) was performed on iPS-RPE
cells from the two MFRP-mutant patients before and after AAV-huMFRP
treatment. Selected areas were trimmed for ultrathin sectioning and
stained with uranyl acetate before visualization by EM.31
Measurement of transepithelial resistance. The transepithelial resistance

(TER) of confluent, pigmented iPS-RPE monolayers cultured on permeable transwell filters was measured using an epithelial volt-ohm meter
(EVOM2) (World Precision Instruments, Sarasota) according to the manufacturer’s instructions.32 For trans-well culture system in this study, there
are four wells for each line of P1, P1 after AAV-MFRP treated, P2, P2 after
AAV-MFRP treated and wild-type control. Each well would be measured
three times at each time point (weekly). The net TER was calculated by
subtracting the background measurement obtained from cell-free, matrigel-coated transwell filters, and then multiplying the difference by the area
of the transwell filter to obtain values in Ω/cm2. The net TER comparison
of patient-specific iPS-RPE lines before and after AAV-MFRP treated was
conducted using ratio paired t-test statistical analyses.
Quantitative fundus autofluorescence imaging. Mice were anesthetized

with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine
(10 mg/kg). Pupils were dilated to an ~2.5 mm (range 2.1–2.9) diameter
by administering 1% tropicamide and 2.5% phenylephrine 15 minutes
before image acquisition. The fundus was aligned and focused using the
near infrared reflectance (NIR-R; 820 nm) mode using high sensitivity to
ensure an evenly illuminated fundus, followed by lowering the sensitivity to make the retinal details visible. The retina was then preexposed at
488 nm in AF mode for 20 seconds to bleach the visual pigment. The detector sensitivity was set at an optimal range that was then used for all AF
imaging. To determine reproducibility, two images were acquired in each
of the two separate sessions. During each session, neither the mouse nor
the camera was moved. Between the two sessions, the image was realigned
and refocused, and the mouse was repositioned.33

Electroretinogram (ERG). ERGs were conducted on Mfrprd6/Mfrprd6 mice

as described previously.19 All manipulations were conducted under dim red
www.moleculartherapy.org vol. 22 no. 9 sep. 2014
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light, and Espion ERG Diagnosys equipment (Diagnosys LLC, Lowell, MA)
was used for the recordings. Adult C57BL/6 (B6) mice were tested at the
beginning of each session as controls to ensure both eyes had the same amplitude. Before each ERG recording, Mfrprd6/Mfrprd6 mice that were subretinally
injected with AAV2/8(Y733F)-mMfrp were dark-adapted for 12 hours and
then anesthetized by intraperitoneal injection of 10% ketamine-xylazinePBS solution. Topical proparacaine and tropicamide (1%) were used for local
anesthesia, and phenylephrine (2.5%) was used for pupillary dilation.
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6.
7.

8.

9.

Histology and immunofluorescence of the AAV transduced eyes. After

subretinal injection of AAV2/8-mMfrp, Mfrprd6/Mfrprd6 mice were sacrificed; then, both eyes were enucleated and fixed in 1:2x Karnovsky fixative
(2% Paraformaldehyde and 1.5% glutaraldehyde) for 24 hours. The eyes
were embedded in paraffin and sectioned. Retinal sections stained with
hematoxylin and eosin were visualized by light microscopy (Leica DM
5000B, Leica Microsystems, Germany). Retinal frozen sections stained
with MFRP antibody and DAPI as mentioned above and were examined
by fluorescence microscopy (Leica DM 5000B, Leica Microsystems).

SUPPLEMENTARY MATERIAL
Figure S1. Pedigree of Patient 1.
Figure S2. Phase images and teratoma assay of patient-specific iPS
cell lines.
Figure S3. Quantification of RPE markers.
Figure S4. Quantification of MFRP, CTRP5 and β-actin Expression in
MFRP-deficient and CTRP5-overexpressed RPE cells.
Figure S5. Images of immunofluorescence on iPS-RPE.
Table S1. Upregulated proteins in patient-specific iPS-RPE involved
with actin cytoskeleton.
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